Abstract
Idecabtagene vicleucel (ide-cel) is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy approved for treatment of relapsed/refractory multiple myeloma. Given BCMA expression on plasma cells, ide-cel has the potential for significant hypogammaglobulinemia and infections, however there is limited data to date describing this association.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
